Treatment of Primary Aldosteronism and Reversal of Renin Suppression Improves Left Ventricular Systolic Function

Troy H Puar1, Chin Kai Cheong2, Roger S Y Foo3,4

  • 1Department of Endocrinology, Changi General Hospital, Singapore, Singapore.

Insights

Treatment for primary aldosteronism improves subclinical heart dysfunction, as measured by global longitudinal strain (GLS). Renin levels after treatment correlate with improved systolic function, indicating successful reversal of sodium overload.

Area of Science:

  • Cardiology
  • Endocrinology
  • Medical Imaging

Background:

  • Primary aldosteronism (PA) increases cardiovascular risk.
  • Conventional assessment (LVEF) doesn't show improved LV systolic function after PA treatment.
  • Subclinical systolic dysfunction may be present in PA patients.

Purpose of the Study:

  • To assess subclinical left ventricular (LV) systolic function improvement after PA treatment.
  • Utilize speckle-tracking echocardiography and global longitudinal strain (GLS) for assessment.

Main Methods:

  • Prospective study of 57 PA patients.
  • Echocardiography including GLS at baseline and 12 months post-treatment.
  • Ambulatory blood pressure monitoring was also performed.

Main Results:

  • GLS improved post-surgery and post-medication, unlike LVEF.
  • Improved GLS correlated with baseline GLS and increased plasma renin activity.
  • Post-treatment renin levels ≥1 ng/ml/h were associated with GLS improvement.

Conclusions:

  • PA treatment effectively improves subclinical LV systolic dysfunction.
  • Elevated renin post-treatment indicates adequate sodium overload reversal and correlates with better systolic function.
Abstract

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
501
Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
38
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
476
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
23
Mitral Regurgitation III: Medical Management01:25

Mitral Regurgitation III: Medical Management

Mitral regurgitation (MR) is characterized by retrograde blood circulation from the left ventricle into the left atrium due to inadequate mitral valve closure. The severity of the condition, symptoms, and underlying cause determine treatment strategies.Monitoring and Pharmacological TreatmentPatients with mild to moderate MR typically do not need immediate intervention but regular monitoring to assess progression and guide treatment. Patients with mild MR should have an echocardiogram every 3-5...
27
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
429